Table 1.
CLL patient clinical and prognostic features.
| Untreated CLL Patients | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient Number |
Age | Sex | Rai Stage |
Cytogenetics | ZAP-70 | CD38 | CD49d | IGHV | Leukemic marrow involvement (%)- hematopathology |
Leukemic marrow involvement(%)- Flow Cytometry |
| 1 | 70 | M | I | 11 q- | + | - | - | UM | 90 | 86.17%# |
| 2 | 62 | M | 0 | 17p- | - | + | + | M | 90 | 83.28%# |
| 3 | 42 | F | II | Trisomy 12 | + | - | + | UM | 30 | 61.99%# |
| 4 | 86 | M | 0 | 11 q- | + | + | - | UM | 90 | 85.72%# |
| 5 | 78 | F | III | 13q- | - | - | - | N/A | 30 | 30.85%# |
| 6 | 82 | M | I | Trisomy 12 | + | + | + | UM | 80 | 66.05%# |
| 7 | 78 | M | I | 11 q- | - | - | + | UM | 60 | 65.01%# |
| 8 | 72 | F | IV | 13q- | - | - | - | M | 80 | 47.62%# |
| 9 | 72 | M | I | 13q- | - | - | + | M | 90 | 94.95%# |
| 10 | 68 | M | IV | 13q- | - | - | + | M | 95 | 59.72%# |
| 11 | 56 | M | IV | 13q- | + | + | - | UM | 70 | 77.93%# |
| 12 | 75 | M | I | 13q- | - | - | M | 2 | 31.17%# | |
| 13 | 68 | M | II | 13q- | - | - | UM | 80 | 24.15%# | |
| 14 | 73 | F | IV | 13q- | - | - | M | 80 | 90.93%# | |
| 15 | 59 | M | 0 | Trisomy 12 | - | + | M | 75 | 48.64%# | |
| 16 | 80 | M | IV | 13q- | + | - | UM | 75 | 69.36%# | |
| 17 | 69 | M | I | Normal | - | + | UM | 80 | 62.49%# | |
| 18 | 68 | M | I | Normal | + | - | UM | 80 | 92.00%# | |
| 19 | 75 | M | 0 | 13q- | - | + | M | 80 | 94.40%# | |
| 20 | 55 | M | IV | 13q- | - | - | M | 50 | 71.69%# | |
| 21 | 59 | M | III | Trisomy 12 | + | + | + | UM | 95 | 94.00%# |
| 22 | 60 | F | II | N/A | + | + | + | UM | 80 | 27.46%# |
| 23 | 47 | M | I | 13q- | + | + | - | UM | 80 | 80.16%# |
| 24 | 38 | M | I | Normal | + | - | + | M | 20 | 45.72%# |
| 25 | 72 | M | I | 13q- | - | - | + | M | 90 | 77.05%* |
| 26 | 67 | F | II | Normal | - | - | + | M | 90 | 75.14%* |
| 27 | 64 | F | IV | 17p- | + | - | - | UM | 100 | 82.14%* |
| 28 | 68 | M | I | Other | + | + | - | UM | 30 | 87.62%* |
| 29 | 59 | M | II | 17p- | + | + | + | UM | 95 | 94.58%* |
| 30 | 75 | M | 0 | Normal | - | + | + | M | 60 | 67.77%* |
| 31 | 61 | M | I | 11 q- | - | - | UM | 60 | 91.54%* | |
| 32 | 52 | F | I | Other | - | - | UM | 60 | 86.56%* | |
| 33 | 66 | M | IV | Trisomy 12 | + | + | UM | >90 | 88.73%# | |
| 34 | 60 | M | I | 11 q- | + | - | UM | 20 | 68.66% * | |
| 35 | 64 | M | 0 | 11 q- | N/A | - | UM | 20 | 60.88%* | |
| 36 | 53 | M | I | 13q- | - | M | 20 | 47.11%* | ||
| 37 | 86 | M | I | 17p- | - | UM | 60 | 93.58% * | ||
| 38 | 73 | M | I | Normal | + | - | UM | 90 | 86.22% * | |
| 39 | 58 | F | III | 13q- | - | - | M | >90 | 91.36%* | |
| 40 | 60 | M | IV | Normal | - | + | M | >90 | 72.09% * | |
| 41 | 52 | F | I | Normal | + | - | - | UM | 95 | 92.66% * |
| 42 | 75 | F | IV | 11 q- | - | - | - | UM | 90 | 93.05% * |
| 43 | 68 | F | I | 13q- | - | - | - | M | 10 | 13.68%# |
| 44 | 80 | M | I | Trisomy 12 | + | - | + | UM | 90 | 86.29%# |
| 45 | 68 | M | I | 11 q- | - | - | - | UM | 90 | 80.34%# |
| 46 | 58 | M | I | N/A | + | - | - | UM | 90 | 73.12%# |
Each CLL patient’s information is indicated as well as clinically relevant prognostic features including ZAP-70, CD38, and CD49d expression where available, mutational status of the immunoglobulin heavy chain variable region (IGHV), and CLL marrow involvement. 11q deletion (11q-), 17p deletion (17p-), 13q deletion (13q-), prognostic factor positive (+), prognostic factor negative (−), unmutated IGHV (UM), mutated IGHV (M), and not available (N/A). Notation of (#) indicates that the sample was used fresh following ACK lysis whereas (*) designates use of a previously ficolled and cryopreserved sample. Additional patient information can be found in Table S1.